Endocrinologist calls for earlier use of tirzepatide in T2DM patients

Watch this video for updated guidance on both new and established therapies for type 2 diabetes

In this clinical conversation, two Sydney-based doctors discuss the role of the new GIP/GLP-1RA class (tirzepatide) along with the more established treatment options such as insulin and the SGLT2i and GLP-1RA classes.

Watch endocrinologist Professor Ted Wu as he explains the expected responses to tirzepatide and how these compare with other antiglycaemic medications, particularly the GLP-1RA class, for HbA1c lowering and weight reduction.